PET Analysis of Dopaminergic Neurodegeneration in Relation to Immobility in the MPTP-Treated Common Marmoset, a Model for Parkinson's Disease

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Ando, Kiyoshi ^a   Obayashi, Shigeru ^b   Nagai, Yuji ^c   Oh Nishi, Arata ^c   Minamimoto, Takafumi ^c   Higuchi, Makoto ^c   Inoue, Takashi ^a   Itoh, Toshio ^a   Suhara, Tetsuya ^c  

^a CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^b NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^c NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CALLITHRIX; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; LOCOMOTION; MALE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PUTAMEN;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CALLITHRIX; DISEASE MODELS, ANIMAL; DOPAMINE; LOCOMOTION; MALE; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY;

EID: 84867289634     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046371     Document Type: Article

References (50)

1. Bonnet AM, Houeto JL, (1999) Pathophysiology of Parkinson's disease. Biomed Pharmacother 53: 117-121.
2. Olanow CW, (2007) The pathogenesis of cell death in Parkinson's disease-2007. Mov Disord 22 (Suppl 17): S335-342.
3. Cookson MR, (2009) alpha-Synuclein and neuronal cell death. Mol Neurodegener 4: 9.
4. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839-840.
5. Gasser T, (2009) Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med 11: e22.
6. Burns RS, Markey SP, Phillips JM, Chiueh CC, (1984) The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey and man. Can J Neurol Sci 11: 166-168.
7. Langston JW, Langston EB, Irwin I (1984) MPTP-induced parkinsonism in human and non-human primates-clinical and experimental aspects. Acta Neurol Scand Suppl 100: 49-54.
8. Piccinin GL, Piccirilli M, Finali G, Stefano E, (1989) [MPTP: a new chapter in the history of Parkinson's disease]. Riv Neurol 59: 103-107.
9. Snyder SH, D'Amato RJ, (1986) MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture. Neurology 36: 250-258.
10. Tetrud JW, Langston JW (1989) MPTP-induced parkinsonism as a model for Parkinson's disease. Acta Neurol Scand Suppl 126: 35-40.
11. Wichmann T, DeLong MR, (2003) Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder. Ann N Y Acad Sci 991: 199-213.
12. Chen MK, Kuwabara H, Zhou Y, Adams RJ, Brasic JR, et al. (2008) VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. J Neurochem 105: 78-90.
13. Halliday G, Herrero MT, Murphy K, McCann H, Ros-Bernal F, et al. (2009) No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism. Mov Disord 24: 1519-1523.
14. Bergman H, Raz A, Feingold A, Nini A, Nelken I, et al. (1998) Physiology of MPTP tremor. Mov Disord 13 (Suppl 3): 29-34.
15. Forno LS, DeLanney LE, Irwin I, Langston JW, (1993) Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations. Adv Neurol 60: 600-608.
16. Jenner P, Rupniak NM, Rose S, Kelly E, Kilpatrick G, et al. (1984) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci Lett 50: 85-90.
17. Nomoto M, Shimizu T, Iwata S, Kaseda S, Fukuda T, (1999) Metabolism of adenosine increase in the striatum in common marmoset parkinsonism induced by MPTP. Adv Neurol 80: 125-128.
18. Verhave PS, Vanwersch RA, van Helden HP, Smit AB, Philippens IH, (2009) Two new test methods to quantify motor deficits in a marmoset model for Parkinson's disease. Behav Brain Res 200: 214-219.
19. Ando K, Maeda J, Inaji M, Okauchi T, Obayashi S, et al. (2008) Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets. Psychopharmacology (Berl) 195: 509-516.
20. Emborg ME, (2007) Nonhuman primate models of Parkinson's disease. ILAR J 48: 339-355.
21. van Vliet SA, Blezer EL, Jongsma MJ, Vanwersch RA, Olivier B, et al. (2008) Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy. Brain Res 1189: 219-228.
22. Fine A, Hunt SP, Oertel WH, Nomoto M, Chong PN, et al. (1988) Transplantation of embryonic marmoset dopaminergic neurons to the corpus striatum of marmosets rendered parkinsonian by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Progress in brain research 78: 479-489.
23. Eslamboli A, Cummings RM, Ridley RM, Baker HF, Muzyczka N, et al. (2003) Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Experimental neurology 184: 536-548.
24. Hildick-Smith M, (1982) Parkinsonism in the elderly. Curr Med Res Opin 7: 14-22.
25. Nomoto M, Jenner P, Marsden CD, (1985) The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset. Neurosci Lett 57: 37-41.
26. Hantraye P, Loc'h C, Tacke U, Riche D, Stulzaft O, et al. (1986) "In vivo" visualization by positron emission tomography of the progressive striatal dopamine receptor damage occurring in MPTP-intoxicated non-human primates. Life Sci 39: 1375-1382.
27. Luquin MR, Manrique M, Guillen J, Arbizu J, Ordonez C, et al. (2011) Enhanced GDNF expression in dopaminergic cells of monkeys grafted with carotid body cell aggregates. Brain research 1375: 120-127.
28. Schwarz J, (2010) [Nuclear medicine imaging in patients with Parkinson's syndrome: an update]. Nervenarzt 81: 1160-1167.
29. Nagai Y, Obayashi S, Ando K, Inaji M, Maeda J, et al. (2007) Progressive changes of pre- and post-synaptic dopaminergic biomarkers in conscious MPTP-treated cynomolgus monkeys measured by positron emission tomography. Synapse 61: 809-819.
30. Saiki H, Hayashi T, Takahashi R, Takahashi J, (2010) Objective and quantitative evaluation of motor function in a monkey model of Parkinson's disease. J Neurosci Methods 190: 198-204.
31. Masilamoni G, Votaw J, Howell L, Villalba RM, Goodman M, et al. (2010) (18)F-FECNT: validation as PET dopamine transporter ligand in parkinsonism. Experimental neurology 226: 265-273.
32. Brownell AL, Canales K, Chen YI, Jenkins BG, Owen C, et al. (2003) Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model. Neuroimage 20: 1064-1075.
33. Poyot T, Conde F, Gregoire MC, Frouin V, Coulon C, et al. (2001) Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa. J Cereb Blood Flow Metab 21: 782-792.
34. Blesa J, Juri C, Collantes M, Penuelas I, Prieto E, et al. (2010) Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An (18)F-DOPA and (11)C-DTBZ PET study. Neurobiology of disease 38: 456-463.
35. Sasaki E, Suemizu H, Shimada A, Hanazawa K, Oiwa R, et al. (2009) Generation of transgenic non-human primates with germline transmission. Nature 459: 523-527.
36. Tokuno H, Tanaka I, Umitsu Y, Akazawa T, Nakamura Y, (2009) Web-accessible digital brain atlas of the common marmoset (Callithrix jacchus). Neuroscience research 64: 128-131.
37. Eslamboli A, (2005) Marmoset monkey models of Parkinson's disease: which model, when and why? Brain Res Bull 68: 140-149.
38. Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, et al. (2003) Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 100: 2884-2889.
39. Knuesel I, Nyffeler M, Mormede C, Muhia M, Meyer U, et al. (2009) Age-related accumulation of Reelin in amyloid-like deposits. Neurobiology of aging 30: 697-716.
40. Tai YC, Ruangma A, Rowland D, Siegel S, Newport DF, et al. (2005) Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med 46: 455-463.
41. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, et al. (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27: 1533-1539.
42. Lammertsma AA, Hume SP, (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4: 153-158.
43. Stevens SS, Carton AS, Shickman GM, (1958) A scale of apparent intensity of electric shock. J Exp Psychol 56: 328-334.
44. Bjugstad KB, Teng YD, Redmond DE Jr, Elsworth JD, Roth RH, et al. (2008) Human neural stem cells migrate along the nigrostriatal pathway in a primate model of Parkinson's disease. Exp Neurol 211: 362-369.
45. Takagi Y, Takahashi J, Saiki H, Morizane A, Hayashi T, et al. (2005) Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Invest 115: 102-109.
46. Mounayar S, Boulet S, Tande D, Jan C, Pessiglione M, et al. (2007) A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery. Brain 130: 2898-2914.
47. Narabayashi H, (1987) Similarity and dissimilarity of MPTP models to Parkinson's disease: importance of juvenile parkinsonism. Eur Neurol 26 (Suppl 1): 24-29.
48. Masilamoni GJ, Bogenpohl JW, Alagille D, Delevich K, Tamagnan G, et al. (2011) Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. Brain: a journal of neurology 134: 2057-2073.
49. Wullner U, Pakzaban P, Brownell AL, Hantraye P, Burns L, et al. (1994) Dopamine terminal loss and onset of motor symptoms in MPTP-treated monkeys: a positron emission tomography study with 11C-CFT. Experimental neurology 126: 305-309.
50. Nagai Y, Minamimoto T, Ando K, Obayashi S, Ito H, et al. (2012) Correlation between decreased motor activity and dopaminergic degeneration in the ventrolateral putamen in monkeys receiving repeated MPTP administrations: A positron emission tomography study. Neuroscience research.